Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAF1NB)

• Drug Name: Isocarboxazid Drug Info
• Synonyms: BMIH; Benazide; Enerzer; Isocarbonazid; Isocarbossazide; Isocarboxazida; Isocarboxazide; Isocarboxazidum; Isocarboxyzid; Maraplan; Marplan; Marplon; Isocarbossazide [DCIT]; Isocarboxazid (INN); Isocarboxazid [INN:BAN]; Isocarboxazida [INN-Spanish]; Isocarboxazide [INN-French]; Isocarboxazidum [INN-Latin]; Marplan (TN); Ro5-0831; Ro 5-0831/1; N'-Benzyl N-methyl-5-isoxazolecarboxylhydrazide-3; N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide; 1-Benzyl-2-(5-methyl-3-isoxazolyl-carbonyl)hydrazine; 1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-benzylhydrazide; 5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide; 5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1] , [2]

• Therapeutic Class: Antidepressants
• Cross-matching ID:
  PubChem CID: 3759
  ChEBI ID: CHEBI:93635
  CAS Number: CAS 59-63-2
  TTD Drug ID: DMAF1NB
  ACDINA Drug ID: D00331

Molecule-Related Drug Atlas

Drug(s) Targeting Monoamine oxidase type A (MAO-A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[4]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[5]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[6]
TRYPTAMINE	DMAFPHB	N. A.	N. A.	Phase 3	[7]
Psoralen	DMIZJ8M	N. A.	N. A.	Phase 3	[8]
CHF-3381	DMQ2O8V	Neuropathic pain	8E43.0	Phase 2	[9]
Ladostigil	DMJSY3Q	Alzheimer disease	8A20	Phase 2	[10]
CX157	DMS2WB5	Mood disorder	6A60-6E23	Phase 2	[11]
PIPERINE	DMYEAB1	Vitiligo	ED63.0	Phase 1/2	[12]
Desoxypeganine	DMTR7EH	Alcohol dependence	6C40.2	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7204).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011961.
• [3] MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
• [4] Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
• [5] Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
• [6] Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
• [7] Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
• [8] Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
• [9] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [10] Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
• [11] Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
• [12] Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
• [13] Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.